Cardiff Lexington Q2 FY26 net loss more than doubles to $2.48 million; revenue falls 22.57% to $2.16 million
Reuters2026/08/12 15:10- Cardiff Lexington posted a Q2 net loss of $2.48 million, more than doubled from a year earlier.
- Revenue fell 22.57% to $2.16 million year over year, on a lower implicit realization rate of patient case claim settlements.
- Operating results swung to a $544,643 loss from operating income, as selling, general and administrative costs climbed 37.72% to $1.36 million.
- For the six months, net loss widened to $5.57 million, while revenue dropped 23.19% to $4.38 million.
- Cash totaled $217,654 at June 30; July 13 brought a common stock purchase issuing 166,667 commitment shares and 20,619 shares for $30,000.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas
A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.
Franco-Nevada buys A$170 million Bullabulling gold project royalty from Minerals 260
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
